Clinical Trial Update: Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of a venetoclax-based regimen to prevent relapse in MRD-positive acute myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia, Measurable Disease | Phase 2 | Status: TERMINATED